Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation (Nasdaq: QDEL) is a global in vitro diagnostics company that regularly issues news on its products, technologies and financial performance. As a manufacturer of diagnostic solutions spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho generates updates that are relevant to clinicians, laboratory professionals and investors who follow developments in medical diagnostics.
News about QuidelOrtho often covers product clearances and launches, such as FDA 510(k) clearance for the VITROS hs Troponin I Assay to aid in the diagnosis of myocardial infarction, or the availability of the QUICKVUE Influenza + SARS Test, a CLIA‑waived rapid immunoassay that differentiates influenza A, influenza B and SARS‑CoV‑2 from a single sample. These announcements provide insight into how the company is expanding its cardiac, respiratory and point‑of‑care testing portfolios.
The company also issues financial and corporate updates, including quarterly earnings releases, guidance discussions and details of financing arrangements disclosed through press releases and related SEC filings. Investors can track how QuidelOrtho describes its revenue mix, cost‑savings initiatives and capital structure, including credit agreements and refinancing activities.
Another recurring theme in QuidelOrtho’s news flow is educational and thought‑leadership content. Through its Science Bytes podcast, the company highlights topics such as diagnostic trends, early detection of diabetes, the role of informatics in clinical decision‑making and the importance of respiratory testing in urgent care. Episodes feature internal experts and external clinicians and are used to explain how diagnostics intersect with patient care and healthcare economics.
In addition, QuidelOrtho reports on its participation in industry conferences, including events focused on transfusion medicine where it showcases immunohematology products like the MTS DAT Card and ORTHO VISION Platform. For users of this news page, following QDEL news offers a way to monitor product pipeline milestones, regulatory developments, financial disclosures and educational initiatives from a single diagnostics-focused source.
QuidelOrtho (NASDAQ: QDEL), a provider of in vitro diagnostic technologies, announced its participation in two upcoming investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference on June 4 at 9:00 a.m. ET, followed by a fireside chat at the Jefferies Global Healthcare Conference on June 5 at 8:45 a.m. ET. Interested investors can access live webcasts and replays of both events through QuidelOrtho's investor relations website.
QuidelOrtho (Nasdaq: QDEL), a global provider of in-vitro diagnostic technologies, has scheduled its first quarter 2025 financial results announcement for May 7, 2025, after market close. The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day to discuss the results.
Investors can access the call through the company's website at ir.quidelortho.com or by phone using the following dial-in numbers:
- Domestic: 833-470-1428
- International: +1 929-526-1599
- Conference ID: 170283
Presentation materials will be available on the company's Investor Relations page during the call, and a replay will be accessible shortly after the event.
QuidelOrtho (Nasdaq: QDEL) has launched the Results Manager™ System, an advanced informatics solution designed for laboratories in community hospitals and point-of-care settings. The system offers key features including:
- Real-time quality monitoring for instruments and assays
- Operational efficiency through auto-verification and simplified rule-writing
- Seamless connectivity with multiple instruments
- Enhanced clinical decision-making capabilities
- Cost-effective deployment with easy installation
The system addresses critical challenges such as rising test volumes, staffing shortages, and increasing complexity while maintaining focus on patient care. Early trial users, including Lab Manager Steve Mulliner from MB Healthcare Services , reported positive feedback on the system's intuitive interface and efficiency improvements. QuidelOrtho is now launching the Results Manager system worldwide, with availability varying by country.
QuidelOrtho (NASDAQ: QDEL), a global provider of innovative in-vitro diagnostic technologies, has announced its participation in the 46th Annual Raymond James Institutional Investor Conference. The company's management team will deliver a presentation on Wednesday, March 5, 2025, at 8:40 a.m. ET / 5:40 a.m. PT.
Investors and interested parties can access both the live webcast and replay of the presentation through the 'Events & Presentations' section on QuidelOrtho's Investor Relations website at https://ir.quidelortho.com. The company specializes in diagnostic technologies for point-of-care settings, clinical labs, and transfusion medicine.
QuidelOrtho (QDEL) reported Q4 2024 revenue of $708 million, down from $743 million year-over-year, primarily due to lower COVID-19 and influenza revenue. Q4 non-respiratory revenue was $565 million, while respiratory revenue decreased 18% to $143 million.
Full-year 2024 revenue reached $2.8 billion, compared to $3.0 billion in 2023. The company reported a GAAP net loss of $2.03 billion for 2024, including a $1.82 billion non-cash goodwill impairment charge. Adjusted EBITDA was $543 million with a 19.5% margin, down from $723 million and 24% margin in 2023.
Looking ahead, QuidelOrtho issued 2025 guidance projecting revenue between $2.60-$2.81 billion, adjusted EBITDA of $575-$615 million, and adjusted EBITDA margin of 22%. The company expects a $55 million negative impact from foreign currency exchange based on January 2025 rates.
QuidelOrtho (NASDAQ: QDEL) has announced preliminary unaudited revenue for Q4 2024, with expected total reported revenues ranging between $702 million to $707 million, aligning with previously announced guidance. The breakdown includes:
- Non-respiratory revenue: $561-563 million
- Respiratory revenue: $141-143 million
The company had a transformative 2024, focusing on high-growth opportunities, leadership realignment, and implementing cost-saving measures. QuidelOrtho plans to release complete Q4 and full-year 2024 financial results on February 12, 2025, followed by a conference call at 2:00 p.m. PT / 5:00 p.m. ET.
QuidelOrtho (QDEL), a global provider of in-vitro diagnostic technologies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on Monday, January 13, 2025, at 7:30 a.m. PST / 10:30 a.m. EST. Investors and interested parties can access both the live webcast and replay through the 'Events & Presentations' section on QuidelOrtho's investor relations website.
QuidelOrtho (QDEL) has announced the pricing of a secondary offering where Carlyle Partners VI Cayman Holdings will sell 8,260,183 shares of common stock. Goldman Sachs & Co. is serving as the sole underwriter for the offering, which is expected to close on November 21, 2024. QuidelOrtho will not receive any proceeds from this transaction as all proceeds will go to the selling stockholder. The offering is being conducted through an effective shelf registration statement filed with the SEC.